Why Stage 2 breast cancer patient had to delay her treatment: Lancet study flags poor detection and access to therapies

This is the gap that has been flagged by the latest Lancet study, which shows that compared to high income countries, where ...

Teva Reaches License Deal With Prestige Biopharma for Cancer Medication in Europe

Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of ...
TipRanks on MSN

Teva enters Tuznue license agreement with Prestige Biopharma

Teva (TEVA) entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue, a biosimilar to Herceptin, across a ...

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ® , a biosimilar to Herceptin ® ...
MedPage Today on MSN

Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer

B ERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in ...
CURE

Presurgical Enhertu Combo Elicits Response Benefit in HER2+ Early Breast Cancer

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...